Project Grant DP2EB041546
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $855K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Oak Ridge, TN 37831, USA
Similar Awards
- The National Institute of Biomedical Imaging and Bioengineering awarded $447,728 to the University of California, Santa Barbara on August 5, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to design new bifunctional chelators that enable diagnostic imaging and targeted alpha particle therapy for cancer treatment. The project addresses two key limitations in alpha particle emitter-based radiopharmaceutical therapy: the...
- The National Cancer Institute awarded Illinois Institute of Technology $648,992 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop antibody chelator conjugates for targeted radionuclide therapy of triple-negative breast cancer. The award funds development and in vitro and in vivo evaluation of antibody chelator conjugates (ACCs) containing monoclonal antibodies with high affinity for validated therapeutic targets in triple-negative breast cancer paired with...
- The National Cancer Institute, within the Department of Health and Human Services National Institutes of Health, awarded The University of Texas Southwestern Medical Center $639,514 on June 1, 2026, for mechanistic characterization of NVL inhibition by benzothiazepinones as a non-genotoxic chemotherapy strategy under the Cancer Biology Research program (CFDA 93.396). The award funds research to define the catalytic mechanism of NVL, an essential AAA+ ATPase required for large ribosomal subunit...
- The National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the Department of Health and Human Services National Institutes of Health, awarded the University of Texas at Arlington $339,676 on August 18, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop light-responsive osmium compounds as metallo-reagents for biomedical imaging and photoactivation. The project develops osmium-based...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $595,041 to Georgia TECH Research Corp on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate redox and lipid metabolism as determinants of radiotherapy resistance in head and neck cancer. The award funds research examining how targeted disruption of tumor redox and lipid metabolism through molecular therapies and dietary intervention can...
- The National Cancer Institute awarded New York University $595,993 on July 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop integrated biologic technologies for selective inhibition of intracellular oncoproteins. The project aims to establish a platform technology that enables direct and selective manipulation of intracellular molecules, particularly driver oncoproteins and their interactions, with the long-term goal of addressing undruggable targets in cancer....
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded $644,423 to Sloan-Kettering Institute for Cancer Research on June 18, 2026, under the Cancer Treatment Research program (CFDA 93.395). The recipient will develop short-wave infrared (SWIR) Cerenkov luminescence imaging (SWIR-CLI) to visualize the distribution of therapeutic radiotracers and improve monitoring of targeted radiotherapy. Current Cerenkov luminescence imaging requires light-tight...
- The National Institute of General Medical Sciences awarded MD Anderson Cancer Center $451,000 on August 7, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop integrative computational tools linking nuclear structure to gene regulation in situ. The research program will create novel computational frameworks and proof-of-concept datasets that systematically measure nuclear morphology features—including micronuclei, ploidy variation, and chromatin...
- The National Institutes of Health Office of the Director awarded a Cooperative Agreement of $554,674 to Temple University on April 20, 2026, to develop and validate a multiorgan microphysiological platform for discovering and screening therapeutics to treat radiation-induced vascular injury. The award is made under the Trans-NIH Research Support program (CFDA 93.310). The recipient will integrate microfluidic models of the blood-brain barrier, gut, and lung into a multiorgan RadChip platform...
- The National Institute of Biomedical Imaging and Bioengineering awarded The Regents of the University of California, operating Lawrence Berkeley National Laboratory, $312,165 on June 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop Time-of-Flight Multi-Photon Emission Tomography (TOF-MPET) for direct imaging of therapeutic radionuclides in cancer treatment. The project addresses limitations in current imaging...